Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Change in Receivables (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Change in Receivables for 15 consecutive years, with $8000.0 as the latest value for Q2 2025.

  • Quarterly Change in Receivables rose 366.67% to $8000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $7000.0 through Dec 2025, up 216.67% year-over-year, with the annual reading at $7000.0 for FY2025, 216.67% up from the prior year.
  • Change in Receivables hit $8000.0 in Q2 2025 for Guided Therapeutics, up from -$1000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $22000.0 in Q4 2021 to a low of -$32000.0 in Q3 2022.
  • Historically, Change in Receivables has averaged $769.23 across 5 years, with a median of -$1000.0 in 2023.
  • Biggest YoY gain for Change in Receivables was 600.0% in 2022; the steepest drop was 1700.0% in 2022.
  • Year by year, Change in Receivables stood at $22000.0 in 2021, then plummeted by 245.45% to -$32000.0 in 2022, then soared by 112.5% to $4000.0 in 2023, then tumbled by 150.0% to -$2000.0 in 2024, then soared by 500.0% to $8000.0 in 2025.
  • Business Quant data shows Change in Receivables for GTHP at $8000.0 in Q2 2025, -$1000.0 in Q1 2025, and -$2000.0 in Q4 2024.